semaglutide dementia Study finds Novo Nordisk's Ozempic may reduce Associations of semaglutide with first‐time

Discover how BPC-157 enhances nitric oxide production to boost blood flow by up to 152%

Need assistance with navigating your options

Certified Medical Team Administered by RNs for safety and precision Premium Ingredients Pharmaceutical-grade nutrients for optimal results Personalized Protocols Tailored to your health goals and lifestyle FAQs Maintenance: 1-2x/month | Intensive: Weekly for 4-6 weeks None

Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit

64 Monarda didyma essential oil reduces the activity of glucose-6-phosphate dehydrogenase, citrate synthase, isocitrate dehydrogenase and -ketoglutarate dehydrogenase in Carbapenem-resistant Klebsiella pneumoniae

In a phase 3 trial (REDEFINE-2) of adults with T2DM and a BMI of 27 kg/m 2 and above, combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide resulted in greater weight loss than placebo at 68 weeks (13.7% vs 3.4%)